Shareholder Derivative

Shareholders say in a <strong><a href="http://www.courthousenews.com/wp-content/uploads/2018/09/Sharehold.Deriv_.pdf">federal derivative complaint</a></strong> that directors of Ophthotech Corp. overhyped the prospects of their experimental macular degeneration drug Fovista, whose failure whacked 86 percent off the share prices, erasing nearly $1.2 billion in market capitalization.

MANHATTAN — Shareholders say in a federal derivative complaint that directors of Ophthotech Corp. overhyped the prospects of their experimental macular degeneration drug Fovista, whose failure whacked 86 percent off the share prices, erasing nearly $1.2 billion in market capitalization.

Categories / Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.